Showing 871-880 of 20379 results for "".
Cardiometabolic Risk Reduction in Native Americans
https://reachmd.com/programs/lipid-luminations/cardiometabolic-risk-reduction-in-native-americans/5987/Joining host Dr. Alan Brown, Ralph LaForge, clinical exercise physiologist at Duke University in the department of endocrinology, and senior faculty consultant to the diabetes division of the US Indian Health Service, discusses the health issues of the Native American population, and some of the novPolycystic Ovary Disease
https://reachmd.com/programs/lipid-luminations/polycystic-ovary-disease/3180/Host Dr. Larry Kaskel welcomes Dr. Tara Dall, board-certified lipidologist at Advanced Lipidology in Wisconsin, to discuss chronic anovulation and hyperandrogenism, and its association with an increased risk of diabetes, metabolic syndrome and cardiac problems. She will also highight treatAesthetic Laser Innovators Discuss What Is Next
https://reachmd.com/programs/modern-aesthetics-focus-on-energy-based-devices/aesthetic-laser-innovators-discuss-what-is-next/56627/A roundtable discussion with Jill S. Waibel, MD, FACS, FAAD; R. Rox Anderson, MD, FAAD; Roy Geronemus, MD; and E. Victor Ross, MD, FAADAPRIL Uncovered: An Upstream Driver in IgAN
https://reachmd.com/programs/cme/april-uncovered-an-upstream-driver-in-igan/54680/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.IgAN SOC: Strengths and Limits
https://reachmd.com/programs/cme/igan-soc-strengths-and-limits/54682/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
https://reachmd.com/programs/cme/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
https://reachmd.com/programs/cme/translating-guidelines-to-action-in-igan-embracing-a-simultaneous-dual-concordant-approach/54687/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Emerging Evidence: IgAN Disease-Modifying Agents
https://reachmd.com/programs/cme/emerging-evidence-igan-disease-modifying-agents/54684/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Emerging Therapies in IgAN: Who Could Benefit the Most?
https://reachmd.com/programs/cme/emerging-therapies-in-igan-who-could-benefit-the-most/54685/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Mechanism-Based Targeting: Why APRIL Matters in IgAN
https://reachmd.com/programs/cme/mechanism-based-targeting-why-april-matters-in-igan/54681/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.